Matthew F Brown Selected Research

quinoxaline-2-carboxylic acid (4- carbamoyl- 1- (3- fluorobenzyl)- 2,7- dihydroxy- 7- methyloctyl)amide

1/2010	CCR1 antagonists: what have we learned from clinical trials.
10/2003	CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew F Brown Research Topics

Disease

5	Autoimmune Diseases (Autoimmune Disease) 11/2020 - 05/2004
4	Rheumatoid Arthritis 10/2018 - 10/2003
4	Neoplasms (Cancer) 01/2018 - 01/2010
3	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2017 - 01/2010
3	Infections 09/2014 - 01/2012
2	Arthritis (Polyarthritis) 01/2018 - 12/2016
2	Multiple Sclerosis 01/2010 - 10/2003
1	Psoriatic Arthritis 10/2018
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 10/2018
1	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2018
1	Inflammation (Inflammations) 01/2018
1	Prostatic Neoplasms (Prostate Cancer) 01/2018
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2017
1	Genetic Translocation (Chromosomal Translocation) 01/2017
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 12/2016
1	Non-alcoholic Fatty Liver Disease 01/2016
1	Communicable Diseases (Infectious Diseases) 09/2014
1	Cross Infection (Nosocomial Infection) 06/2013
1	Colonic Neoplasms (Colon Cancer) 01/2012
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2010
1	Hyperlipidemias (Hyperlipidemia) 10/2003
1	Hypertension (High Blood Pressure) 10/2003

Drug/Important Bio-Agent (IBA)

5	Phosphotransferases (Kinase)IBA 01/2018 - 01/2012
3	Janus Kinase InhibitorsIBA 11/2020 - 12/2010
3	tofacitinibIBA 01/2018 - 10/2003
3	Imatinib Mesylate (Gleevec)FDA Link 01/2017 - 01/2010
2	CytokinesIBA 10/2018 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2012
2	Tyrosine (L-Tyrosine)FDA Link 01/2018 - 01/2012
2	Janus KinasesIBA 01/2018 - 12/2010
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2017 - 01/2010
2	Pharmaceutical PreparationsIBA 09/2014 - 02/2014
2	quinoxaline-2-carboxylic acid (4- carbamoyl- 1- (3- fluorobenzyl)- 2,7- dihydroxy- 7- methyloctyl)amideIBA 01/2010 - 10/2003
1	TYK2 Kinase (Tyrosine Kinase 2)IBA 11/2020
1	Monoclonal AntibodiesIBA 10/2018
1	SulfonamidesIBA 01/2018
1	Erythropoietin FDA Link 01/2018
1	abrocitinibIBA 01/2018
1	PropaneIBA 01/2018
1	MTOR InhibitorsIBA 01/2018
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018
1	Thrombopoietin (c-mpl Ligand)IBA 01/2018
1	PF-06651600IBA 12/2016
1	EnzymesIBA 01/2016
1	Anti-Bacterial Agents (Antibiotics)IBA 09/2014
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 02/2014
1	Polymyxins (Polymyxin)IBA 06/2013
1	SiderophoresIBA 09/2012
1	Monobactams (Monobactam Antibiotics)IBA 09/2012
1	Hydroxamic Acids (Hydroxamic Acid)IBA 01/2012
1	Sunitinib (Sutent)FDA Link 01/2012
1	BX 471IBA 01/2010
1	MLN3897IBA 01/2010
1	Bortezomib (Velcade)FDA Link 01/2010
1	AZD-4818IBA 01/2010
1	Chemokine ReceptorsIBA 05/2004
1	CCR1 ReceptorsIBA 10/2003
1	ChemokinesIBA 10/2003

Therapy/Procedure

1	Radiotherapy 01/2018
1	Drug Therapy (Chemotherapy) 01/2018
1	Therapeutics 02/2014